New target for prostate cancer therapy

July 3, 2012 in Cancer

(Medical Xpress) -- Researchers at Imperial College London have discovered a molecule that plays an important role in driving prostate cancer growth, and could be a target for new therapies.

About 36,000 men are diagnosed with each year in the UK, making it the most common cancer in men. The cancer depends on male hormones to progress, as these hormones stimulate the to divide, enabling the to grow.

The new study, published in , found that increase the production of a molecule called miR-27a in prostate cancer cells in the laboratory, and that this molecule stimulates the cells to grow. An inhibitor of miR-27a halved the growth rate of , suggesting that such a molecule might have therapeutic potential.

miR-27a belongs to a class of molecules called microRNAs – short strands of genetic material which are increasingly understood to play an important role in regulating gene activity. MicroRNAs are appealing as therapeutic targets since compared with proteins, it is much easier to design and synthesise inhibitory that can get into cells easily. Another microRNA inhibitor is already being tested in humans in combination with chemotherapy for prostate cancer.

“This is a promising first step towards a possible new therapy, but there are many hurdles to overcome first,” said Claire Fletcher, the study’s first author, who is studying for a PhD in Dr Charlotte Bevan’s lab in the Department of Surgery and Cancer at Imperial.

“MicroRNAs have only been known about for the last 10 years, but we’re now realising how important they are in regulating which genetic messages are read and thus which proteins are produced. This study shows that miR-27a is an important intermediary that links hormones with prostate . We’ve demonstrated that inhibiting this molecule can suppress prostate cancer growth in the lab. The next step is to test that concept in an animal model. It will be several years at least before we can test any new treatments in humans.”

The subset of genes that are turned on in a cell determine how the cell behaves. If a gene is switched on, its code is copied onto a messenger molecule and the message is translated to make a protein, which carries out a specific function. MicroRNAs work by interfering with the messenger so that the protein does not get made.

Each microRNA can regulate many genes. The new study found that one of the targets of miR-27a is a tumour suppressor called prohibitin, which the Imperial team previously discovered is a regulator of prostate cancer growth.

The research was funded by the Medical Research Council, Cancer Research UK and Prostate Cancer UK.

More information: CE Fletcher et al. ‘Androgen-regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer.’ Human Molecular Genetics (2012) 21 (14):3112-3127.doi: 10.1093/hmg/dds139

Journal reference: Human Molecular Genetics search and more info website

Provided by Imperial College London search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Small cancer risk following CT scans in childhood and adolescence confirmed

The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...

Cancer created 4 hours ago | popularity not rated yet | comments 0

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...

Cancer created 5 hours ago | popularity not rated yet | comments 0

Novel RNA-based classification system for colorectal cancer

A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...

Cancer created 6 hours ago | popularity not rated yet | comments 0

Low radiation scans help identify cancer in earliest stages

A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...

Cancer created 7 hours ago | popularity not rated yet | comments 0

Poliovirus vaccine trial shows early promise for recurrent glioblastoma

An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

Cancer created 9 hours ago | popularity not rated yet | comments 0


If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.

Antidepressant reduces stress-induced heart condition

A drug commonly used to treat depression and anxiety may improve a stress-related heart condition in people with stable coronary heart disease, according to researchers at Duke Medicine.